Paris, France – November 5^th, 2024

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced that Pierre Bélichard, CEO, and Christelle Dumoussaud, CFO, will present an overview of the Company and participate in
1-on-1 meetings with institutional investors at the following events:

• Inv€$tival Showcase in London, UK, November 18, 2024

Enterome’s presentation is scheduled at 13:30 GMT on the “Biotech Late Growth” stage.

 

• Jefferies’ London Healthcare Conference, UK, November 19-21, 2024

 

• 43^rd J.P. Morgan Annual Healthcare Conference in San Francisco, USA,
  January 13-16, 2025

 

Enterome’s management team will also attend the 66^th American Society of Hematology (ASH) Annual Meeting and Conference, from December 7-10, 2024, in San Diego, California, and will be available to discuss the latest clinical advances from the company’s onco-hematology pipeline.

Download the press release (.pdf format)